The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | The transformative impact of BCMA-targeting bispecific antibodies in RRMM
Andrew Yee, MD, Massachusetts General Hospital Cancer Center, Boston, MA, highlights the transformative impact of BCMA-targeting therapies in relapsed/refractory multiple myeloma (RRMM). Dr Yee notes that bispecific antibodies, in particular, offer a significant advantage due to their off-the-shelf availability and feasibility for patients in the community, making them a more accessible treatment option. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
BCMA therapies, think about in context, there are therapies that target BCMA. We have different ways of targeting this antigen. We can do it through as an antibody drug conjugate, CAR T-cell therapy, and now as a bispecific antibody. And these therapies which target BCMA have been really transformational in terms of improving outcomes for our patients. What is great about the bispecific antibodies is that they are off the shelf and readily available for our patients...
BCMA therapies, think about in context, there are therapies that target BCMA. We have different ways of targeting this antigen. We can do it through as an antibody drug conjugate, CAR T-cell therapy, and now as a bispecific antibody. And these therapies which target BCMA have been really transformational in terms of improving outcomes for our patients. What is great about the bispecific antibodies is that they are off the shelf and readily available for our patients. CAR T-cell therapies, these are amazing therapies which are transformational, but they are more logistically complicated. They require patients to go to a major medical center. They require a caregiver to be with them. So because of that, there are challenges with broadening their application. Bispecific antibodies, on the other hand, are much more readily accessible, more feasible for patients in the community, which is where the majority of our patients live.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultant for multiple companies.
